藥明生物(2269.HK)漲6% 調研紀要透露今年收入和淨利潤增速在50%左右
格隆匯5月25日丨入選了格隆匯2021年“下注中國”十大核心潛力資產名單的藥明生物(2269.HK)今日明顯走強,盤中一度漲6.01%報116.4港元,市值逼近4900億港元。一份藥明生物的調研交流紀要內容透露:“公司今年CMO項目的收入貢獻以及項目數都會有比較大的提升,今年保守估計有6個CMO項目,且不包括可能從外部拿到的其他訂單。公司給市場的反饋是今年收入和淨利潤同比增長50%左右。”

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.